| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
8-Epidiosbulbin E acetate targets bacterial plasmids and cancer cells. It exhibits broad-spectrum plasmid-curing activity against multidrug-resistant (MDR) bacteria, including vancomycin-resistant enterococci. It also induces tumor cell death and inhibits tumor growth. Its mechanism of action in cancer cells likely involves the induction of apoptosis, although the specific molecular targets are still under investigation.
|
|---|---|
| ln Vitro |
In vitro, 8-Epidiosbulbin E acetate demonstrates significant biological activity. It exhibits broad-spectrum plasmid-curing activity against multidrug-resistant (MDR) bacteria. It also shows time- and dose-dependent liver injury in mice, indicating hepatotoxic potential. Its ability to induce tumor cell death makes it a potential candidate for cancer therapy.
|
| ln Vivo |
8-Epidiosbulbin Eacetate can be used to create models of liver damage in animals.
In vivo, 8-Epidiosbulbin E acetate has been shown to cause time- and dose-dependent liver injury in mice. This hepatotoxicity is a significant finding that highlights the compound's potential for toxicity. Its broad-spectrum plasmid-curing activity suggests potential in vivo efficacy against MDR bacterial infections, although specific studies are limited. |
| Enzyme Assay |
The in vitro antibacterial assay for 8-Epidiosbulbin E acetate involves testing its ability to cure plasmids from multidrug-resistant bacteria. The compound is serially diluted and added to bacterial cultures. After incubation, the loss of plasmids is assessed by measuring the loss of antibiotic resistance markers or by plasmid DNA isolation and gel electrophoresis. The minimum concentration required for plasmid curing is determined.
|
| Cell Assay |
In vitro cell culture studies for 8-Epidiosbulbin E acetate are performed in cancer cell lines to assess its cytotoxic effects. Cells are treated with varying concentrations of the compound, and cell viability is assessed using an MTT or SRB assay. Apoptosis is detected by flow cytometry using Annexin V/PI staining. The expression of proteins involved in apoptosis is analyzed by Western blotting.
|
| Animal Protocol |
In vivo animal experiments for 8-Epidiosbulbin E acetate have been performed in mice to study its hepatotoxicity. The compound is administered orally or intraperitoneally, and liver function is assessed by measuring serum levels of ALT and AST. Histopathological examination of liver tissues is performed to evaluate the extent of liver injury. Its antibacterial efficacy could be studied in mouse models of infection.
|
| ADME/Pharmacokinetics |
8-Epidiosbulbin E acetate has a molecular formula of C21H24O7 and a molecular weight of 388.41 g/mol. It is a solid compound that is soluble in organic solvents like DMSO. It is typically stored as a powder at -20°C for long-term stability. Its stability is maintained under recommended storage conditions. It is an organooxygen compound and an organic heterotricyclic compound.
|
| Toxicity/Toxicokinetics |
Toxicological data for 8-Epidiosbulbin E acetate indicate that it causes time- and dose-dependent liver injury in mice. This hepatotoxicity is a significant concern and highlights the need for careful evaluation of its safety profile. As a research compound, it is not intended for human use. Standard safety precautions should be followed.
|
| References |
|
| Additional Infomation |
8-Epididyin E acetate is an oxygen-containing organic compound and an organic heterocyclic tricyclic compound. [(1R,2S,3S,5S,8S,10S,11R,13R)-8-(furan-3-yl)-10-methyl-6,15-dioxo-7,14-dioxatetracyclo[11.2.1.02,11.05,10]hexadecane-3-yl] acetate has been reported in yam, and relevant data are available.
8-Epidiosbulbin E acetate is a research compound with no clinical approval. It is a valuable tool for studying plasmid curing in MDR bacteria and for understanding the mechanisms of bacterial resistance. Its ability to induce tumor cell death makes it a compound of interest for cancer research. However, its hepatotoxic potential limits its therapeutic applicability and requires further investigation. |
| Molecular Formula |
C21H24O7
|
|---|---|
| Molecular Weight |
388.411067008972
|
| Exact Mass |
388.152
|
| CAS # |
91095-48-6
|
| PubChem CID |
134715250
|
| Appearance |
Pale purple to purple solid powder
|
| LogP |
2.2
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
28
|
| Complexity |
705
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O([C@H]1C[C@H]2C(O[C@H](C3=COC=C3)C[C@@]2(C)[C@@H]2C[C@H]3OC(=O)[C@@H]([C@@H]12)C3)=O)C(=O)C
|
| InChi Key |
DYSOIAQEKRDXRB-GFTCARDDSA-N
|
| InChi Code |
InChI=1S/C21H24O7/c1-10(22)26-16-7-15-20(24)28-17(11-3-4-25-9-11)8-21(15,2)14-6-12-5-13(18(14)16)19(23)27-12/h3-4,9,12-18H,5-8H2,1-2H3/t12-,13+,14+,15+,16-,17-,18+,21-/m0/s1
|
| Chemical Name |
[(1R,2S,3S,5S,8S,10S,11R,13R)-8-(furan-3-yl)-10-methyl-6,15-dioxo-7,14-dioxatetracyclo[11.2.1.02,11.05,10]hexadecan-3-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~257.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5746 mL | 12.8730 mL | 25.7460 mL | |
| 5 mM | 0.5149 mL | 2.5746 mL | 5.1492 mL | |
| 10 mM | 0.2575 mL | 1.2873 mL | 2.5746 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
